Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ELTX vs. BMEA, XBIT, VSTM, LFVN, MGNX, PRQR, SLN, CYBN, PGEN, and LYELShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Biomea Fusion (BMEA), XBiotech (XBIT), Verastem (VSTM), LifeVantage (LFVN), MacroGenics (MGNX), ProQR Therapeutics (PRQR), Silence Therapeutics (SLN), Cybin (CYBN), Precigen (PGEN), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Biomea Fusion XBiotech Verastem LifeVantage MacroGenics ProQR Therapeutics Silence Therapeutics Cybin Precigen Lyell Immunopharma Biomea Fusion (NASDAQ:BMEA) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Which has better valuation & earnings, BMEA or ELTX? Elicio Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.05Elicio Therapeutics$2.30M22.89-$35.19M-$6.95-0.70 Is BMEA or ELTX more profitable? Biomea Fusion's return on equity of -118.90% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Elicio Therapeutics N/A -555.45%-177.34% Which has more risk and volatility, BMEA or ELTX? Biomea Fusion has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Do analysts recommend BMEA or ELTX? Biomea Fusion currently has a consensus price target of $39.36, suggesting a potential upside of 830.58%. Elicio Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 104.92%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Elicio Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in BMEA or ELTX? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to BMEA or ELTX? In the previous week, Biomea Fusion had 14 more articles in the media than Elicio Therapeutics. MarketBeat recorded 14 mentions for Biomea Fusion and 0 mentions for Elicio Therapeutics. Biomea Fusion's average media sentiment score of 0.48 beat Elicio Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Overall Sentiment Biomea Fusion Neutral Elicio Therapeutics Neutral Does the MarketBeat Community believe in BMEA or ELTX? Biomea Fusion received 50 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Elicio Therapeutics an outperform vote while only 68.29% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5668.29% Underperform Votes2631.71% Elicio TherapeuticsOutperform Votes685.71% Underperform Votes114.29% SummaryBiomea Fusion beats Elicio Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.66M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.7010.5990.1317.19Price / Sales22.89196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book3.615.094.784.78Net Income-$35.19M$151.83M$120.31M$225.60M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.7912 of 5 stars$4.88-3.8%$10.00+104.9%-16.0%$52.66M$2.30M-0.70N/ABMEABiomea Fusion3.902 of 5 stars$5.85+3.7%$39.36+572.9%-71.0%$212.00MN/A-1.4150Analyst ForecastXBITXBiotechN/A$6.92-0.4%N/A+59.9%$210.94M$4.01M-6.41100VSTMVerastem3.7857 of 5 stars$4.68+4.5%$12.50+167.1%-47.9%$208.29M$10M-1.4050Analyst ForecastNews CoverageLFVNLifeVantage4.5473 of 5 stars$16.49+2.8%N/A+176.9%$206.54M$196.01M50.13260Analyst ForecastNews CoverageGap DownHigh Trading VolumeMGNXMacroGenics3.543 of 5 stars$3.23+0.9%$7.63+136.1%-68.2%$202.72M$139.77M-2.03430PRQRProQR Therapeutics2.0476 of 5 stars$2.47-12.7%$7.60+207.7%+30.8%$201.75M$7.05M-8.13180Gap DownHigh Trading VolumeSLNSilence Therapeutics3.1687 of 5 stars$6.74+4.5%$57.20+748.7%-58.7%$201.73M$31.55M-4.11100CYBNCybin1.5422 of 5 stars$9.91+1.3%$138.00+1,292.5%N/A$198.12MN/A-1.4850PGENPrecigen3.4635 of 5 stars$0.67-0.3%$7.00+939.2%-32.5%$197.28M$3.96M-1.23202Negative NewsLYELLyell Immunopharma2.2211 of 5 stars$0.67-0.5%$1.00+49.2%-69.4%$195.87M$63,000.00-0.85270Gap Down Related Companies and Tools Related Companies BMEA Competitors XBIT Competitors VSTM Competitors LFVN Competitors MGNX Competitors PRQR Competitors SLN Competitors CYBN Competitors PGEN Competitors LYEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
